Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download PROJECT: Anti-HIV carbonucleoside phosphonates
Transcript
PROJECT: Anti-HIV carbonucleoside phosphonates DEVELOPMENT OF A NEW CLASS OF ACTIVE MOLECULES AGAINST HIV HEALTH & BIOTECHNOLOGIES IP Patent, software, N/A... TECHNOLOGY Nucleoside analogs DESIRED PARTNERSHIP CONTACT Business Development [email protected] Licensing, partnership, co-development INVENTORS / LABORATORIES IBMM: Max Mousseron Institute of Biomolecules, University of Montpellier, CNRS, ENSCM CONTEXT Acquired immunodeficiency syndrome (AIDS) is one of the leading causes of death in the world. While combined therapies, such as anti-retroviral therapy (highly active antiretroviral therapy - HAART), have contributed significantly to virus elimination and have improved quality of life for people, problems such as intolerance and the emergence of resistance among members of particular classes of pharmaceutical drugs remain a major problem for successful long-term treatment. As a result, there is an ongoing need for new anti-HIV drugs with greater power and improved pharmacokinetic properties. BENEFITS The originality of this project’s invention resides in the non-natural L configuration of designed carbocyclic phosphonate nucleosides. The use of L-nucleoside analogs as antiviral agents leads to an antiviral activity that is comparable, and sometimes better than, their D counterparts, along with a more favorable toxicolgical profile and better metabolic stability. APPLICATIONS Chemotherapy for HIV and other infectious diseases in which nucleoside analogs have been identified as antiviral drugs. +33 (0)4 48 19 30 01
